why Cogent Biosciences Inc [COGT] is a Good Choice for Investors After New Price Target of $17.73

Cogent Biosciences Inc [NASDAQ: COGT] gained 23.35% or 1.77 points to close at $9.35 with a heavy trading volume of 31631949 shares.

It opened the trading session at $8.915, the shares rose to $10.23 and dropped to $8.8, the range by which the price of stock traded the whole day. The daily chart for COGT points out that the company has recorded 19.87% gains over the past six months.

If we look at the average trading volume of 1.77M shares, COGT reached to a volume of 31631949 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Here is what top equities market gurus are saying about Cogent Biosciences Inc [COGT]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for COGT shares is $17.73 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on COGT stock is a recommendation set at 1.50. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

Scotiabank have made an estimate for Cogent Biosciences Inc shares, keeping their opinion on the stock as Sector Outperform, with their previous recommendation back on March 07, 2025. The new note on the price target was released on December 11, 2024, representing the official price target for Cogent Biosciences Inc stock. Previously, the target price had yet another drop from $14 to $8, while Robert W. Baird kept a Neutral rating on COGT stock.

The Price to Book ratio for the last quarter was 9.61, with the Price to Cash per share for the same quarter was set at 2.16.

Trading performance analysis for COGT stock

Cogent Biosciences Inc [COGT] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 31.69. With this latest performance, COGT shares gained by 65.78% in over the last four-week period, additionally plugging by 19.87% over the last 6 months – not to mention a rise of 19.87% in the past year of trading.

Cogent Biosciences Inc [COGT]: A deeper dive into fundamental analysis

Return on Equity for this stock declined to -70.93%, with Return on Assets sitting at -70.93%.

Cogent Biosciences Inc [COGT]: An earnings per share (EPS) analysis

The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for COGT. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Cogent Biosciences Inc go to 28.29%.

An analysis of Institutional ownership at Cogent Biosciences Inc [COGT]

There are presently around $118.62%, or 118.81% of COGT stock, in the hands of institutional investors. The top three institutional holders of COGT stocks are: POINT72 ASSET MANAGEMENT, L.P. with ownership of 10.47 million shares, which is approximately 10.5506%. COMMODORE CAPITAL LP, holding 9.74 million shares of the stock with an approximate value of $$82.09 million in COGT stocks shares; and COMMODORE CAPITAL LP, currently with $$78.07 million in COGT stock with ownership which is approximately 9.3313%.

The DBT News
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.